Virax Biolabs Group (Virax Biolabs Group) Total Liabilities : $0.92 Mil (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Total Liabilities?

Virax Biolabs Group's Total Liabilities for the quarter that ended in Sep. 2023 was $0.92 Mil.

Virax Biolabs Group's quarterly Total Liabilities declined from Sep. 2022 ($1.14 Mil) to Mar. 2023 ($0.91 Mil) but then increased from Mar. 2023 ($0.91 Mil) to Sep. 2023 ($0.92 Mil).

Virax Biolabs Group's annual Total Liabilities increased from Mar. 2021 ($0.87 Mil) to Mar. 2022 ($1.25 Mil) but then declined from Mar. 2022 ($1.25 Mil) to Mar. 2023 ($0.91 Mil).

Virax Biolabs Group Total Liabilities Historical Data

The historical data trend for Virax Biolabs Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Total Liabilities Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Total Liabilities

1.24

0.87

1.25

0.91

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Total Liabilities	Get a 7-Day Free Trial			1.05	1.25	1.14	0.91	0.92

Virax Biolabs Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Virax Biolabs Group's Total Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.908	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.91

Total Liabilities	=	Total Assets (A: Mar. 2023 )	-	Total Equity (A: Mar. 2023 )
	=	9.812	-	8.904
	=	0.91

Virax Biolabs Group's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.787	+	(0.132	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.92

Total Liabilities	=	Total Assets (Q: Sep. 2023 )	-	Total Equity (Q: Sep. 2023 )
	=	7.025	-	6.106
	=	0.92

Virax Biolabs Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.